31 August 2022FeaturesJurisdiction reportsKate Legge and Emily Dwyer

Australia: Regulatory exclusivities for pharmaceuticals

The Australian exclusivity regime for medicines differs from those in place in the northern hemisphere. It also contains subtleties that sponsors (originator and generic/biosimilars) need to know to determine the impact on generic/biosimilar market formation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Australia extends EPO fast-track patent examinations

21 June 2022 Australia’s IP office, IP Australia, and the European Patent Office (EPO) have agreed to continue the patent prosecution highway (PPH) programme, following a successful pilot phase.

Patents

Australia reverses DABUS AI inventorship ruling

13 April 2022 The Federal Court of Australia has overturned its prior ruling that artificial intelligence (AI) can be a named inventor on a patent application, striking down the last year’s surprising win for Stephen Thaler and his ongoing AI inventorship campaign.

UK firms Venner Shipley and AA Thornton combine

UPC docs 'excessively redacted' under GDPR claims transparency lawyer

L'Oréal sued over virtual makeup try-on simulator

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Q&A: EagleView counsel maps out route to IPR victory

WIPO in Saudi Arabia to finalise design law treaty

Douwe Egberts enjoys double shot over Nestlé in coffee patent rivalry

Startup CFO’s betrayal is a lesson in preparing for the worst

Australia: Regulatory exclusivities for pharmaceuticals

More on this story

Editor's picks

Editor's picks

More articles